Benign Prostatic Hyperplasia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Benign Prostatic Hyperplasia – Drugs In Development, 2024 report and make more profitable business decisions.
Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, and difficulty starting a urine stream. Treatment options for BPH include surgery and medications.
The Benign Prostatic Hyperplasia drugs in development market research report provide comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Benign Prostatic Hyperplasia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 29 molecules, with 28 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Benign Prostatic Hyperplasia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Benign Prostatic Hyperplasia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Benign Prostatic Hyperplasia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AiViva BioPharma IncAphios Corp
Aquestive Therapeutics Inc
ASKA Pharmaceutical Holdings Co Ltd
BCWorld Pharm Co Ltd
Central Drug Research Institute
Chengdu Dikang Pharmaceuticals Co Ltd
Chong Kun Dang Pharmaceutical Corp.
Curadis GmbH
Curigin Co Ltd
DMK Pharmaceuticals Corp
DongKoo Bio & Pharma Co Ltd
Dongkook Pharmaceutical Co Ltd
GemVax & KAEL Co Ltd
GENUONE Sciences Inc
Geropharm
Hanmi Pharmaceuticals Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Kwang Dong Pharmaceutical Co Ltd
Nymox Pharmaceutical Corp
Sentan Pharma Inc
ValiRx Plc
Veru Inc
Xuanzhu Biotechnology Co Ltd
Yuyu Pharma Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Benign Prostatic Hyperplasia reports